Effects of ranitidine bismuth citrate on Helicobacter pylori motility, morphology and survival.
OBJECTIVE
The effects of the anti-ulcer agents ranitidine bismuth citrate (RBC), ranitidine hydrochloride (R) and colloidal bismuth citrate (BC), on Helicobacter pylori motility, morphology and survival were examined to determine whether the clinical effectiveness of RBC might be linked to a specific action that inhibits bacterial motility.


METHODS
H. pylori from patients with duodenal ulcer or non-ulcer dyspepsia were exposed to RBC and BC at bismuth concentrations ranging from 12.5 to 50 microg/mL, and R at ranitidine concentrations ranging from 12.5 to 50 microg/mL for a brief period (< 15 min), 6 h and 24 h. Bacterial motility was assessed with a Hobson BacTracker, bacterial morphology by transmission electron microscopy, and growth inhibition by counting colony-forming units.


RESULTS
H. pylori motility was diminished with RBC and BC but not R. However, the effect of RBC was markedly greater than that of BC at each bismuth concentration and time of exposure tested: (i) brief exposure to RBC/bismuth 50 microg/mL but not to BC, resulted in a significant loss of motility without loss of viability or change in cell morphology, and (ii) bacteria were immobilized, and lost viability after exposure to RBC/bismuth 50 microg/mL for 24 h but not to BC. Morphological destruction caused by RBC differed from that by BC: after 24 h exposure to the highest concentration tested, cell fragmentation and flagella detachment occurred more frequently with BC than RBC, but the latter produced greater disruption of intracellular structures.


CONCLUSIONS
RBC suppresses growth of H. pylori, and has a specific inhibitory effect on the bacterial motor mechanism. These pharmacological actions are likely to contribute to the clinical effectiveness of the agent.
Worku
M L
ML
Department of Medical Microbiology, Imperial College School of Medicine, St. Mary's Hospital, London, UK.
Sidebotham
R L
RL
Karim
Q N
QN
D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D001729:Bismuth / Q000494:pharmacology*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000502:physiology / Q000648:ultrastructure; D006801:Humans; D008854:Microscopy, Electron; D009942:Organometallic Compounds / Q000494:pharmacology; D011899:Ranitidine / Q000031:analogs & derivatives* / Q000494:pharmacology
D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; C073340:ranitidine bismuth citrate; D011899:Ranitidine; C002791:bismuth tripotassium dicitrate; D001729:Bismuth